Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ono Pharmaceutical Co. Ltd.
Industry Sector: HealthTechnology
CEO: Gyo Sagara
Number Of Employees: 3,853
Enterprise Value: $6,529,232,717
PE Ratio: 10.34
Exchange/Ticker 1: Tokyo:4528
Exchange/Ticker 2: N/A
Latest Market Cap: $5,352,277,358
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Dec 10, 2024
Deals
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | Oct 31, 2024
Deals
Trend watch: Degrader deals show glues are sticking
At least seven molecular glue degrader deals announced this year; less deal activity for classical PROTACs
BioCentury | Oct 24, 2024
Management Tracks
Junaid Bajwa joins Flagship as senior partner, head of U.K.
Plus: Promotions at Citigroup and updates from FDA’s CDRH, LigaChem, Alphina, Kenai and Precision Medicine
BioCentury | Oct 15, 2024
Deals
Three new partnerships that could be worth over $1B
Deals report: Astellas-AviadoBio in CNS gene therapy deal, Merck-Mestag to identify inflammatory targets, Eli Lilly-KeyBioscience tackling obesity
BioCentury | Oct 1, 2024
Product Development
BCMA CAR Ts diverge in early lines, as Carvykti dominates market
In BioCentury’s latest Clinical Report, AbbVie hits in Parkinson’s, plus data from Shattuck, Merck and Celldex
BioCentury | Sep 20, 2024
Management Tracks
Mark Bachleda takes the helm at Eyconis
Plus: Steve Caffé to lead regulatory affairs at Disc, and updates from Stalicla and AN Venture
BioCentury | May 28, 2024
Deals
J&J adds bispecific for atopic dermatitis via deal with Numab
Ten-figure M&A transaction with Swiss antibody company gives the pharma an immunology asset targeting IL-4RA and IL-31; builds on Proteologix deal
Items per page:
1 - 10 of 693